Late Breaking Abstract Parallel Session 2

Description

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Presentations

5:15 PM - 5:30 PM
Apr 29 2026
Washington, D.C.

Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With Primary Biliary Cholangitis Treated With Seladelpar: Results From the ASSURE Study up to 30 Months

Gideon M Hirschfield, FRCP, PhD , Abstract Presenter
6:15 PM - 6:30 PM
Apr 29 2026
Washington, D.C.

Once-monthly Efimosfermin Alfa for Up to 48 Weeks in Metabolic Dysfunction-Associated Steatohepatitis with F2/F3 Fibrosis: Results from a Phase 2, Open-Label Extension Study

Mazen Noureddin , Abstract Presenter

Objectives

  • Review findings from recent clinical trials related to treatments for hepatitis, MASH, and PBC.